Literature DB >> 6106342

Effect of a somatostatin analog on insulin requirement and hormone levels in 6 insulin-dependent juvenile-onset diabetics subjected to artificial pancreas.

G Lenti, M Trovati, R Lorenzati, F Vitelli, V Tagliaferro, A Marocco, G Pagano.   

Abstract

This study was performed in order to investigate the effect of a 12-h infusion of the somatostatin selective analog D-Trp8, D-Cys14 Serono, (SRIF-A), on insuli requirement and C-peptide (CP), growth hormone (GH) and glucagon (IRG) levels in 6 insulin-dependent diabetics submitted to 60-h artificial pancreas (Biostator Miles) metabolic control from 2000 of the first day to 0800 of the fourth day. Meals were given at 1200 and 1700 of the second and third day. Before meals and 1-2 h after meals, plasma levels of CP, GH and IRG were measured. The two 12-h periods (midday-midnight) with and without continuous SRIF-A 12-h infusion (40 microgram/h) were considered. The SRIF-A infusion caused a 20% reduction in insulin requirement (p < 0.05) and a slight but significant reduction of GH levels (p < 0.05). CP and IRG were unaffected.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6106342     DOI: 10.1007/bf02582072

Source DB:  PubMed          Journal:  Acta Diabetol Lat        ISSN: 0001-5563


  20 in total

1.  The diabetogenic action of somatostatin in healthy subjects and in maturity onset diabetics.

Authors:  W Waldhäusl; P Bratusch-Marrain; R Dudczak; E Deutsch
Journal:  J Clin Endocrinol Metab       Date:  1977-05       Impact factor: 5.958

2.  Antidiabetic action of somatostatin--assessed by the artificial pancreas.

Authors:  C Meissner; C Thum; W Beischer; G Winkler; K E Schröder; E F Pfeiffer
Journal:  Diabetes       Date:  1975-11       Impact factor: 9.461

3.  Somatostatin analogs which inhibit glucagon and growth hormone more than insulin release.

Authors:  C Meyers; A Arimura; A Gordin; R Fernandez-Durango; D H Coy; A V Schally; J Drouin; L Ferland; M Beaulieu; F Labrie
Journal:  Biochem Biophys Res Commun       Date:  1977-01-24       Impact factor: 3.575

4.  Somatostatin analogs as glucagon suppressants in diabetes.

Authors:  V Schusdziarra; J Rivier; R Dobbs; M Brown; W Vale; R Unger
Journal:  Horm Metab Res       Date:  1978-11       Impact factor: 2.936

5.  Somatostatin. Its possible role in carbohydrate homeostasis and the treatment of diabetes mellitus.

Authors:  J E Gerich
Journal:  Arch Intern Med       Date:  1977-05

6.  Prevention of human diabetic ketoacidosis by somatostatin. Evidence for an essential role of glucagon.

Authors:  J E Gerich; M Lorenzi; D M Bier; V Schneider; E Tsalikian; J H Karam; P H Forsham
Journal:  N Engl J Med       Date:  1975-05-08       Impact factor: 91.245

7.  The effect of hyperglucagonemia on blood glucose concentrations and on insulin requirements in insulin-requiring diabetes mellitus.

Authors:  W L Clarke; J V Santiago; D M Kipnis
Journal:  Diabetes       Date:  1978-06       Impact factor: 9.461

8.  Growth hormone's role in diabetic microangiopathy.

Authors:  K Lundbaek
Journal:  Diabetes       Date:  1976       Impact factor: 9.461

9.  Glucagon regulation of plasma ketone body concentration in human diabetes.

Authors:  D S Schade; R P Eaton
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

10.  Influence of somatostatin on carbohydrate disposal and absorption in diabetes mellitus.

Authors:  J Wahren
Journal:  Lancet       Date:  1976-12-04       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.